2016 Annual Report

Progress through Partnership

Message from Chair of the Board and Executive Director

Marcel Tanner and Bernard Pécoul

We have evolved, expanded, and adapted. Our mission, however, remains unchanged: to bring the best science to neglected patients, by discovering and developing new treatments for diseases where commercial R&D is not enough.

Read Message

 

Impact

DNDi in Numbers

Treatments icon

7 treatments delivered since 2003

People trained icon

More than 3,000 people trained since 2010

Clinical platforms icon

4 clinical research platforms and networks in disease-endemic countries since 2003

People screened icon

590,170 people screened for sleeping sickness in DRC in 2016

Treatments distributed icon

More than 430 million ASAQ treatments for malaria distributed since 2007

Paediatric HIV icon

Recommended in 2016 by WHO Superbooster Therapy for Paediatric HIV/TB

14

new chemical entities in DNDi's R&D pipeline in 2016

Compounds screened icon

388,461 compounds screened in 2016

EUR 34M

in-kind contributions from partners since 2007

People working for DNDi at partner orgs icon

722 people working for DNDi in partner organizations in 2016

Nomination icon

Nomination of 3 pre-clinical candidates (for leishmaniasis and filarial diseases) in 2016

Universities icon

5 universities from the UK, the US, and India joined the Open Synthesis Network in 2016

R & D

Diseases Portfolio

Click on the icons below to find out about the diseases DNDi is researching and the status of our R&D projects:

Leishmaniasis

Sleeping Sickness

Chagas Disease

Filaria

Mycetoma

Paediatric HIV

Hepatitis C

Drug-resistant Infections

GARDP launched with three programmes starting for drug-resistant infections

Building on DNDi’s experience in developing a research & development pipeline for neglected diseases, the Global Antibiotic Research & Development Partnership was officially launched in May 2016. A joint initiative between WHO and DNDi, with seed funding from Germany, the UK, Switzerland, the Netherlands, South Africa, and Médecins Sans Frontières, GARDP’s vision is a world where everyone in need of antibiotics receives effective, appropriate, and affordable treatment, irrespective of where they live.

Read

In Focus

Dr Robert Don

How has drug discovery at DNDi evolved over the past decade?

Dr Robert Don reflects on challenges and achievements in drug discovery at DNDi over the last 12 years.

Read

What norms and principles should govern the financing of health R&D?

The need for alternative models such as DNDi, to boost innovation and access for neglected tropical diseases, where the commercial model clearly fails to meet the needs of patients in low- and middle-income countries, has long been recognized. But in recent years, the global environment has evolved.

Read

Strengthening endemic country capacity to advance new treatments

Since its inception in 2003, DNDi has worked to integrate capacity strengthening into its projects in a sustainable manner, through knowledge sharing and technology transfers. The objective is to increase the chances of registration, uptake, and sustainable access of new treatments for neglected diseases and, ultimately, to support the transfer of ownership to disease-endemic countries.

Read

The challenge of conducting clinical studies in remote areas

Because sleeping sickness occurs in very remote areas of the DRC, there are major operational challenges that need to be overcome to conduct clinical studies.

Read

Bringing treatment to the forgotten 99%

In Colombia, stakeholders from Government, academia, NGOs, and patient organizations are working in partnership with DNDi aiming to eliminate barriers to diagnosis and treatment for Chagas disease in the country for its estimated 437,000 patients.

Read

An unattainable cure: Countries rich, poor, and in the middle, all struggling to access HCV drugs

The powerful generation of new direct-acting antivirals to treat HCV have become the poster child for the prohibitive price of medicines in many countries. New treatment regimens combining DAAs cost upwards of USD 100,000 in the US, and EUR 40,000 in European countries.

Read

Photo credits: DNDi/Neil Brandvold, DNDi/Paul Kamau, Shutterstock/iStock, DNDi/Kishore Pandit, DNDi/Fabio Nascimento, DNDi/Abraham Ali/Imageworks, DNDi/João Roberto Ripper.